Literature DB >> 8974063

Chronic low-dose treatment with enalapril induced cardiac regression of left ventricular hypertrophy.

N Makino1, M Sugano, T Hata, S Taguchi, T Yanaga.   

Abstract

Numerous studies suggest that the renin angiotensin system (RAS) is involved in the development of cardiac hypertrophy. In the present study we produced cardiac hypertrophy in rats subjected to abdominal aortic banding and also induced cardiac regression by the administration of an angiotensin converting enzyme (ACE) inhibitor, enalapril, at 3, 10 and 30 mg/kg/day. Each drug was administered to the rats for 6 weeks from 6 weeks after aortic banding. The left ventricular weight significantly decreased at 10 and 30 mg/kg/day of enalapril as well as the systolic blood pressure. Using the reverse transcriptase polymerase chain reaction, the increased levels of ACE and AT1 mRNA were significantly inhibited in the aortic banding rats treated with the above concentrations of enalapril. The ACE activity in both the plasma and heart tissue preparations was significantly inhibited by enalapril. Similar observations were also seen after the administration of angiotensin type 1 receptor blockade, E-4177, into the aortic banding rats. The treatment with enalapril at 3 mg/kg/day did not reduce the left ventricular weight or the systolic blood pressure in the aortic banding rats. However, this low-dose treatment did significantly decrease the left ventricle to body weight ratio in the aortic banding rats without a reduction of the systolic blood pressure. Therefore, using the low-dose enalapril, the ACE activity in plasma was in part inhibited and the levels of ACE mRNA also decreased in the heart tissue of aortic banding rats, while the level of AT1 mRNA showed no such decrease. These results thus indicate that chronic ACE inhibitor at low doses has a beneficial effect on the regression in the pressure-induced cardiac hypertrophy. It is thus assumed that this effect may also contribute to the presence of an alternate pathway for the conversion of angiotensin I to angiotensin II which might also act as a possible mechanism for cardiac regression.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8974063     DOI: 10.1007/bf00408664

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  24 in total

1.  Regression of hypertrophy after myocardial infarction is produced by the chronic blockade of angiotensin type 1 receptor in rats.

Authors:  N Makino; T Hata; M Sugano; I M Dixon; T Yanaga
Journal:  J Mol Cell Cardiol       Date:  1996-03       Impact factor: 5.000

2.  Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family.

Authors:  P Fort; L Marty; M Piechaczyk; S el Sabrouty; C Dani; P Jeanteur; J M Blanchard
Journal:  Nucleic Acids Res       Date:  1985-03-11       Impact factor: 16.971

3.  Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation.

Authors:  H Schunkert; V J Dzau; S S Tang; A T Hirsch; C S Apstein; B H Lorell
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

4.  Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats.

Authors:  W Linz; B A Schölkens; D Ganten
Journal:  Clin Exp Hypertens A       Date:  1989

5.  Angiotensins and the failing heart. Enhanced positive inotropic response to angiotensin I in cardiomyopathic hamster heart in the presence of captopril.

Authors:  H Hirakata; F M Fouad-Tarazi; F M Bumpus; M Khosla; B Healy; A Husain; H Urata; H Kumagai
Journal:  Circ Res       Date:  1990-04       Impact factor: 17.367

6.  A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril.

Authors:  W Linz; B A Schölkens
Journal:  Br J Pharmacol       Date:  1992-04       Impact factor: 8.739

7.  Effect of angiotensin converting enzyme inhibitor on regression in cardiac hypertrophy.

Authors:  N Makino; H Matsui; K Masutomo; T Hata; T Yanaga
Journal:  Mol Cell Biochem       Date:  1993-02-17       Impact factor: 3.396

8.  In vitro pharmacology of a novel non-peptide angiotensin II-receptor antagonist, E4177.

Authors:  H Okunishi; K Song; Y Oka; T Kobayashi; T Kawamoto; H Ishihara; N Mori; M Miyazaki
Journal:  Jpn J Pharmacol       Date:  1993-07

9.  The renin-angiotensin system and volume overload-induced cardiac hypertrophy in rats. Effects of angiotensin converting enzyme inhibitor versus angiotensin II receptor blocker.

Authors:  M Ruzicka; B Yuan; E Harmsen; F H Leenen
Journal:  Circulation       Date:  1993-03       Impact factor: 29.690

10.  Chronic low-dose treatment with perindopril improves cardiac function in stroke-prone spontaneously hypertensive rats by potentiation of endogenous bradykinin.

Authors:  P Gohlke; T Unger
Journal:  Am J Cardiol       Date:  1995-11-24       Impact factor: 2.778

View more
  1 in total

Review 1.  A story of two ACEs.

Authors:  Ursula Danilczyk; Urs Eriksson; Michael A Crackower; Josef M Penninger
Journal:  J Mol Med (Berl)       Date:  2003-03-28       Impact factor: 4.599

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.